Headache And Episodic Neurologic Disorders

Headache is among the oldest documented complaints in medicine, referenced in ancient Sumerian texts and Egyptian papyri dating back thousands of years. Despite this long history, a systematic approach to classifying headache disorders only emerged in the twentieth century. For centuries, headache was attributed to humoral imbalances, demonic possession, or vascular engorgement, and treatment ranged from trepanation to bloodletting. The modern clinical framework recognizes headache as a complex neurobiological phenomenon involving peripheral and central sensitization, cortical spreading depression, and dysfunction within the trigeminovascular system. Understanding this evolution is critical for USMLE Step 2 CK, where distinguishing primary from secondary headache disorders determines the urgency of workup and management.

The central clinical question this lesson addresses is: Given a patient presenting with headache or an episodic neurological symptom, how do you systematically identify red flags, differentiate primary from secondary causes, and initiate appropriate management? Mastering this framework is essential for both clinical practice and high-yield board performance.

The foundational step in headache evaluation is determining whether the presentation is a primary headache disorder — in which headache itself is the disease — or a secondary headache disorder — in which headache is a symptom of an underlying pathological process such as subarachnoid hemorrhage, meningitis, or intracranial mass. The ICHD-3 classification organizes headache into these two broad categories and further subdivides them into specific syndromes with operationalized diagnostic criteria. An additional category, painful cranial neuropathies and other facial pains, addresses conditions like trigeminal neuralgia. Understanding these principles underpins every clinical vignette on Step 2.

The flowchart above represents the essential clinical algorithm tested on USMLE Step 2. When a patient presents with headache, your first task is to screen for red flags using the SNOOP₄ mnemonic. If no red flags are present, the history and physical examination will guide you toward one of the three major primary headache categories. If red flags are identified, the specific constellation of findings dictates the urgency and type of workup — a thunderclap headache reaching maximum intensity within seconds demands immediate non-contrast CT followed by lumbar puncture if imaging is negative, whereas progressive headache with papilledema warrants MRI with venography to evaluate for cerebral venous thrombosis or mass lesion. The bottom row reminds clinicians that episodic neurologic conditions such as transient ischemic attack, seizure, syncope, and vertigo can present with headache as a co-occurring or confounding symptom.

Migraine Pathophysiology

The contemporary understanding of migraine has shifted from a purely vascular model to a neurovascular model. The process begins with activation of the trigeminovascular system, in which peripheral sensory neurons originating from the trigeminal ganglion innervate the meningeal blood vessels and dura mater. Upon stimulation, these C-fibers release vasoactive neuropeptides — most importantly calcitonin gene-related peptide (CGRP) — which cause vasodilation, mast cell degranulation, and plasma protein extravasation, collectively termed neurogenic inflammation. Afferent signals travel to the trigeminal nucleus caudalis in the brainstem, then ascend to the thalamus and cortex, producing the conscious perception of pain. Central sensitization, characterized by allodynia and hyperalgesia, develops when repetitive nociceptive input lowers the pain threshold of second-order neurons.

Cortical Spreading Depression and Aura

In migraine with aura, the neurological symptoms are attributed to cortical spreading depression (CSD), a wave of neuronal and glial depolarization that sweeps across the cortex at approximately 3 mm/min. CSD begins in the occipital lobe in most cases, explaining the predominance of visual aura (scintillating scotomata, fortification spectra). As the wave propagates, it can produce somatosensory, language, or motor symptoms. CSD also activates trigeminal afferents, linking aura to the subsequent headache phase. Importantly, aura develops gradually over 5−60 minutes and fully resolves, distinguishing it from the abrupt onset of TIA or seizure — a high-yield distinction for boards.

Tension-Type Headache Mechanisms

The pathophysiology of tension-type headache (TTH) is less clearly defined than migraine but involves both peripheral and central mechanisms. Episodic TTH may be driven by increased pericranial myofascial tenderness and peripheral nociceptive input, while chronic TTH shows evidence of central sensitization with decreased pain thresholds on pressure algometry. Unlike migraine, TTH is not associated with CGRP release or significant neurogenic inflammation, which explains why triptans are ineffective for this condition.

Cluster Headache and Hypothalamic Activation

Cluster headache, the most severe primary headache disorder, involves activation of the posterior hypothalamus, which functions as a pacemaker for the circadian and circannual periodicity of attacks. PET imaging during cluster attacks shows increased blood flow in the ipsilateral posterior hypothalamic gray matter. The trigeminal-autonomic reflex drives the associated parasympathetic symptoms — conjunctival injection, lacrimation, nasal congestion, and ptosis/miosis — via the superior salivatory nucleus and sphenopalatine ganglion. The combination of severe unilateral orbital pain with ipsilateral autonomic features is pathognomonic for cluster headache.

USMLE Step 2 CK requires precise differentiation among the major primary headache syndromes. The table below compares migraine, tension-type headache, and cluster headache across the clinical features most commonly tested in board-style questions. Memorizing these distinguishing features is one of the highest-yield investments for the neurology section.

Secondary Headache Red Flags in Detail

• Thunderclap headache (peak intensity within seconds): subarachnoid hemorrhage until proven otherwise; workup with non-contrast CT head → lumbar puncture if CT negative within 6 hours
• New headache in patient >50 years: consider giant cell arteritis (temporal arteritis); check ESR/CRP, start empiric corticosteroids, temporal artery biopsy
• Headache with fever and meningismus: bacterial meningitis; empiric antibiotics before LP if imaging is needed first
• Progressive headache with papilledema: raised intracranial pressure from mass lesion, idiopathic intracranial hypertension, or cerebral venous sinus thrombosis
• Headache worse with Valsalva or positional change: posterior fossa lesion (Chiari malformation, colloid cyst of third ventricle) or intracranial hypotension

The following worked example mirrors the format and complexity of a USMLE Step 2 CK clinical vignette. Work through each step to build your systematic approach to headache diagnosis and management.

One of the most clinically important — and frequently tested — skills is distinguishing migraine aura from other episodic neurologic events, particularly transient ischemic attack and seizure. The temporal profile of the event is the single most useful distinguishing characteristic. A thorough understanding of these differences prevents unnecessary interventions (e.g., anticoagulation for migraine aura mistaken as TIA) and ensures timely treatment of true emergencies.

Understanding primary headache management requires familiarity not only with established therapies but also with the rapidly evolving landscape of mechanism-based treatments. The advent of CGRP-targeted therapies has transformed migraine prophylaxis and represents the first class of medications designed specifically for migraine based on pathophysiological understanding. Additionally, recognizing the overlap between headache and other episodic neurologic disorders — particularly medication overuse headache (MOH) and the concept of chronic migraine — is increasingly tested on Step 2.